Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody which has completed pivotal phase 2 clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, and Omburtamab 03-133 that is in phase 1 clinical trials for the treatment of intrathecal immunotherapy for CNS/leptomeningeal metastases.
In addition, its product pipeline includes huB7-H3 for the treatment of systemic solid tumors.
The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.
Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -0.15 Increased by 0.00% | -0.14 Decreased by -7.14% |
| Feb 29, 24 | -0.02 Decreased by -166.67% | -0.20 Increased by +90.00% |
| Nov 13, 23 | -0.18 Increased by +71.43% | -0.19 Increased by +5.26% |
| Aug 10, 23 | -0.14 Increased by +85.11% | -0.24 Increased by +41.67% |
| May 8, 23 | -0.15 Increased by +76.56% | -0.32 Increased by +53.13% |
| Mar 30, 23 | 0.03 Increased by +103.53% | -0.46 Increased by +106.52% |
| Nov 7, 22 | -0.63 Increased by +4.55% | -0.71 Increased by +11.27% |
| Aug 8, 22 | -0.94 Decreased by -77.36% | -0.67 Decreased by -40.30% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 20.45 M Increased by +63.15% | -7.75 M Increased by +73.32% | Decreased by -37.88% Increased by +83.65% |
| Jun 30, 23 | 20.75 M Increased by +92.19% | -6.30 M Increased by +85.11% | Decreased by -30.37% Increased by +92.25% |
| Mar 31, 23 | 20.25 M Increased by +93.12% | -5.10 M Increased by +82.08% | Decreased by -25.17% Increased by +90.72% |
| Dec 31, 22 | 31.45 M Increased by +227.64% | -401.00 K Increased by +98.91% | Decreased by -1.28% Increased by +99.67% |
| Sep 30, 22 | 12.54 M Increased by +39.84% | -29.04 M Decreased by -0.61% | Decreased by -231.59% Increased by +28.05% |
| Jun 30, 22 | 10.80 M Decreased by -1.41% | -42.32 M Decreased by -84.49% | Decreased by -391.93% Decreased by -87.12% |
| Mar 31, 22 | 10.49 M Increased by +94.80% | -28.44 M Decreased by -185.12% | Decreased by -271.23% Decreased by -143.70% |
| Dec 31, 21 | 9.60 M Decreased by -53.74% | -36.89 M Decreased by -85.09% | Decreased by -384.38% Decreased by -300.14% |